Protalix Of Israel To Refile For U.S. Approval Of Gaucher's Drug
This article was originally published in PharmAsia News
Executive Summary
Israel's Protalix Biotherapeutics plans to refile a new drug application with U.S. FDA, which rejected its first drug, Uplyso (taliglucerase) for treating Gaucher's disease